in the practice for dentistry in Bergedorf.

As an established specialist practice in Bergedorf, with the dentist and oral surgeon Dr. Mirzaaligoudarzi and his team aim to offer you the best possible treatment through intensive advice and individual solutions. Modernly equipped practice rooms, the latest treatment methods, DVT X-rays (3D) and a highly qualified, friendly and motivated team are at your side.

Dr. med. dent. Mirzaaligoudarzi

Main focus: implantology, oral surgery, functional therapy

Studied dentistry at the University Hospital Eppendorf
Doctorate at the Clinic for Oral and Maxillofacial Surgery under Prof. Dr. schiffner
Further training as a specialist dentist for oral surgery at the Klinikum Bremen Mitte – department for maxillofacial surgery under Prof. Dr. Dr. Rustemeyer
Certified implantologist

Ms. Bouss

Main focus: Dental prosthetics, aesthetic-reconstructive dentistry, periodontics

Updated specialist information on nuwiq – contains data on effective bleeding protection through personalized prophylaxis for twice-weekly administration, business wire

April 2, 2018

Updated Nuwiq ® prescribing information includes data on effective bleeding protection through personalized prophylaxis when administered twice a week

LACHEN, Switzerland – (BUSINESS WIRE) – As announced today by Octapharma, the European Medicines Agency has approved an updated technical update (SmPC) for the drug Nuwiq ®, which contains information on personalized prophylaxis in patients with haemophilia A. The updated technical information is available at https://www.ema.europa.eu/en/medicines/human/EPAR/nuwiq

The new information in the updated information is based on data from the NuPreviq study, in which 66 previously treated adult patients switched from a 1 to 3 month standard prophylactic regimen to a 6 month personalized regimen based on their individual pharmacokinetic (PK) characteristics were. Out of the 66 patients reported in the study, 44 changed to a different prophylactic regimen after PK assessment. Of these, 40 completed 6-month prophylaxis according to the assigned dosing and treatment regimen, and 34 patients (85%) were treated twice a week or less. The mean annual bleeding rate among the 40 patients was 1.2 ± 3.9, 90 percent of the patients had no spontaneous bleeding and 83 percent had no bleeding of any kind. The mean SD dose was 52.2 ± 12.2 IU / kg each Injection (99.7 ± 25.6 IU / kg per week) and there were no treatment-related adverse events.